Skip to main content

Security report for angelinipharma.com

Angelini Pharma S.p.a. · Healthcare · Italy

Medium risk. 2 critical or high findings in SSL/TLS and GDPR outside view.

Security score

66/100

Risk levelMedium

0–100, higher is better. How it is calculated

Angelini Pharma S.p.a. is a large international pharmaceutical company focused on research, development, and commercialization of health solutions primarily in the Central Nervous System (CNS), Rare Diseases, and Consumer Health sectors. The company maintains a strong market position with multiple country-specific domains and a clear commitment to sustainability, ethics, and transparency. Their website reflects a professional and comprehensive digital presence targeting healthcare professionals, patients, and partners. Technically, the website employs modern JavaScript libraries such as jQuery, Slick Slider, and Piwik PRO analytics with a consent management platform, indicating a mature digital infrastructure. The site is mobile-optimized, accessible, and SEO-friendly, though no CMS or hosting provider details were explicitly detected. From a security perspective, the site enforces HTTPS and uses cookie consent mechanisms, but lacks explicit security policy pages and incident response contacts. No critical vulnerabilities or exposed sensitive data were found. The absence of WHOIS registration data is a concern but is mitigated by the professional appearance and extensive content. Overall, the website is trustworthy and well-maintained, though improvements in transparency around security policies and incident response would enhance trust. The domain WHOIS inconsistency warrants further verification to confirm registration legitimacy.

Scanned

NIS2 and GDPR posture

GDPR outside view
68/ 100 · Medium
Checks completed
7of 7

NIS2 Art. 21(2)

  1. (a) Risk analysis and security policies: Not visible from outside
  2. (b) Incident handling: One indicator
  3. (c) Business continuity, backups and crisis management: Not visible from outside
  4. (d) Supply chain security: Not visible from outside
  5. (e) Secure acquisition, development and maintenance, including vulnerability handling: Partly checked
  6. (f) Assessing the effectiveness of security measures: Not visible from outside
  7. (g) Cyber hygiene and security training: Not visible from outside
  8. (h) Cryptography and encryption: Partly checked
  9. (i) HR security, access control and asset management: One indicator
  10. (j) Multi-factor authentication and secured communications: Not visible from outside

This scan rated NIS2 with an earlier keyword method that is no longer shown; rescan for the per-article view. Risk management, continuity, supply chain, training, MFA, management oversight (Art. 20) and incident reporting (Art. 23) need internal evidence, and Guard cannot tell whether NIS2 applies to this organisation.

GDPR is indicative only, based on publicly visible signals: Articles 7, 12, 13 and 32 of Regulation (EU) 2016/679 and Article 5(3) of the ePrivacy Directive. Not a certification or legal assessment.

Priority findings

2 findings rated critical or high. Fix these first.

  1. SSL/TLS

    TLS encrypts the connection and proves the site is really yours. Weak or expiring certificates trigger browser warnings and put traffic at risk.

    • Critical

      Unable to retrieve SSL certificate

      Could not establish secure connection to retrieve certificate information

      What to do: Check if the server is accessible and SSL/TLS is properly configured

  2. GDPR outside view

    These are the privacy signals visitors and data protection authorities look for under GDPR.

    • High

      No Cookie Consent Banner found

      GDPR requires explicit consent for non-essential cookies

      What to do: Implement a cookie consent banner that appears on first visit

Need hands-on remediation? Email guard@offseq.com

Keep watching angelinipharma.com

This scan found 16 issues across 6 checks. Monitoring re-runs those checks daily, emails you when something material changes and records each fix, so you can show progress.

Daily monitoring

Recommended

€25per month

  • TLS certificates and expiry
  • DNS records
  • SPF, DKIM and DMARC
  • Security headers
  • GDPR and NIS2 posture
  • Exposed services
  • Third-party trackers
  • Security score drift

Email alerts on material changes and an exportable JSON history of every change.

Billed monthly to your card. Cancel anytime. The full timeline opens with your unlock code.

Full report

€39.90one-time

  • The complete analysis as a PDF you can cite
  • Email delivery with an unlock code
  • Lifetime access to this report

Prices incl. 21% VAT. Secure checkout by Mollie; sold by SEQ SIA, Latvia.

Results by check

Each check with its score, findings and the evidence it collected.

How this score is calculated

The security score runs 0–100, higher is better. It is the plain average of the security checks that completed in this scan, each counted equally. A check that could not run is left out: it counts neither as a pass nor as a fail.

Counted in this score

SSL/TLS
0
Security headers
90
Email security
55
DNS health
80
Network security
100
GDPR outside view
68
Average
66

Not counted

  • NIS2 outside view: Re-weights evidence from the TLS, email, DNS, network and hygiene checks, so counting it would count that evidence twice. Shown on its own.
  • OffSeq Observations: An AI reading of the site, useful context but not reproducible evidence. Shown on its own.

Findings that cap the score at 49

Each of these is serious on its own, so while any is present the site cannot rate better than high risk, however good the other checks are.

  • The certificate is not trusted by browsers
  • The website is not served over HTTPS
  • A database, remote desktop, file-sharing or Telnet service is reachable from the internet
  • The page loads a script from a compromised source
  • The domain registration has expired
  • SPF authorises every server to send mail as the domain

Partial scans

When the site blocks Guard or most checks cannot run, the score covers only the checks that ran (usually DNS and email), is capped at 75 and is shown as partial, without a risk level.

Risk levels

  • Critical0–25
  • High26–49
  • Medium50–75
  • Low76–100

Breach exposure

Leaked credentials and lookalike domains from OffSeq Breach. The counts are free; the detailed lists are paid add-ons.

Dark web exposure

Add-on

Leaked records that mention angelinipharma.com, from OffSeq Breach.

Total records
168
Employees
0
Customers
9
Third parties
159
Weak passwords
5%

1 subdomain affected

See the 10 newest leaked credentials

A one-off add-on to this report that lists the most recent identifier and password pairs OffSeq Breach holds for angelinipharma.com.

Select it in the checkout above.

Breach keeps ingesting new leaks, so these numbers can grow between scans.

Technical appendix

Business context, site observations and technical notes gathered during the scan, and the standards behind each reference.

Business context

Business profile

Angelini Pharma operates in the healthcare sector with a focus on CNS, Rare Diseases, and Consumer Health. Their business model revolves around pharmaceutical R&D, clinical trials, and product commercialization. The company targets healthcare professionals, patients, and consumers, leveraging a broad international footprint with localized websites. Their market position is strong, supported by recognized certifications such as Top Employer Europe 2025. The company emphasizes sustainability, diversity, and ethics, which align with modern corporate social responsibility trends. Partnerships and licensing out are part of their strategic operations. The presence of multiple country-specific domains indicates a decentralized but coordinated global strategy.

Security posture

The website demonstrates a good security posture with HTTPS enforced and a cookie consent mechanism compliant with GDPR. Use of Piwik PRO analytics with consent tracking shows attention to privacy. However, the absence of a dedicated security policy and incident response contact reduces transparency and preparedness perception. No security headers were explicitly detected in the provided data, suggesting room for improvement. No vulnerabilities or exposed sensitive data were found in the HTML content. The lack of WHOIS data is a potential red flag but may be due to privacy protection or registrar issues. Overall, the security maturity is moderate to good but could be enhanced with explicit policies and security headers.

Recommendations

  1. Publish a dedicated security policy page outlining security practices and commitments.
  2. Provide clear incident response contact information, including security@ or abuse@ email addresses.
  3. Implement and publish a security.txt file to facilitate vulnerability disclosures.
  4. Enhance HTTP security headers such as Content-Security-Policy, Strict-Transport-Security, X-Content-Type-Options, and X-Frame-Options.
  5. Regularly audit and update third-party scripts and libraries to mitigate vulnerabilities.

Contact details published on the site

Addresses
Legal name
Angelini Pharma S.p.a.
Registration number
03907010585
Site observations

Automated reading of the public site. Ratings are indicative.

Business

Company
Angelini Pharma S.p.a.
Description
Angelini is committed to identifying health solutions with a prevalent focus on the areas of Central Nervous System (CNS), including pain, and Rare Diseases. The Company is also a leading player in the Consumer Health sector.
Key services
Research and Development, Clinical Trials, Production and Commercialization of pharmaceutical products, Consumer Health products
Content quality
excellent
Branding
consistent

Technology

Stack
jQuery 3.7.1, jQuery Validation, Slick Slider, Magnific Popup, Piwik PRO Analytics, Flip.js, ACSB Accessibility Plugin
Performance
moderate
Mobile
good
Accessibility
good
SEO
good

Security

Observed score
85/100
Good practices seen
  • HTTPS enforced
  • Cookie consent mechanism implemented
  • No exposed sensitive data in HTML
  • Use of analytics with consent management

Analytics and tracking

Services
Piwik PRO
Tracking level
moderate
Privacy practices
good

Advertising

Tracking pixels
Piwik PRO
Marketing tools
Piwik PRO Consent Management
Transparency
good

Site quality

Design
excellent
User experience
excellent
Content relevance
excellent
Navigation
excellent
Professionalism
excellent
Trustworthiness
high

Key observations

  1. Website is fully accessible with rich content and navigation.
  2. Strong focus on pharmaceutical and healthcare sectors.
  3. Multiple country-specific subdomains indicate international presence.
  4. Comprehensive privacy and cookie policies with consent management.
  5. No visible security policy or incident response contact found.
  6. Use of modern JavaScript libraries and analytics with consent.
  7. No suspicious or malicious content detected.
  8. WHOIS data missing, which reduces trust but site appears professional.
Technical notes

Notes

The website uses a modern JavaScript-based front-end with libraries including jQuery 3.7.1, Slick Slider for carousels, Magnific Popup for modals, and Piwik PRO for analytics and consent management. Accessibility is enhanced via the ACSB plugin. The site is mobile-optimized and SEO-friendly with proper meta tags and Open Graph data. No CMS or hosting provider was explicitly identified. Performance is moderate, likely due to multiple external scripts and media assets. The site structure is clear with comprehensive navigation and localized country sites. Technical debt appears low, but security header implementation could be improved.
Standards and sources

Reference chips under each finding point to the standard, regulation or specification the finding relates to. They are taken from the official datasets below and mapped conservatively: a finding with no defensible link shows none. NIS2 and GDPR references mark where a finding is relevant evidence, not a compliance verdict. Implementing Regulation (EU) 2024/2690 binds digital infrastructure and digital service providers; for other entities it is the most detailed public reading of the Article 21 measures. WCAG, EN 301 549, European Accessibility Act and Web Accessibility Directive references name the requirement an automated accessibility rule relates to; they are not a conformance verdict.

Retrieved 2026-10-25

Reviews of this site

Share your experience with angelinipharma.com. Every review is verified by email and published after moderation.

Overall rating
Select a rating
4000 characters remaining

We’ll email you to confirm your review and keep your details private.

Community rating

No published reviews yet. Be the first to review angelinipharma.com.

Feedback on this report

Rate this report, add an optional comment, and tell us if you want a security specialist to follow up.

Overall report quality
Select a rating
2000 characters remaining

We only use your feedback to improve Guard reports. Contact details are never shared.